Surgical and survival outcomes of neoadjuvant IMRT-based chemoradiotherapy versus upfront surgery in borderline resectable pancreatic cancer: a retrospective cohort study.
코호트
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
152 patients were included, with 109 in the upfront surgery group and 43 in the chemoradiotherapy group.
I · Intervention 중재 / 시술
curative-intent resection
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] Neoadjuvant chemoradiotherapy with IMRT plus gemcitabine and nab-paclitaxel was associated with improved surgical and survival outcomes in patients with BRPC compared to upfront surgery. These findings support the integration of modern chemoradiotherapy into the neoadjuvant treatment paradigm for BRPC and warrant prospective validation.
[BACKGROUND] Borderline resectable pancreatic cancer (BRPC) poses significant surgical challenges due to tumor-vessel involvement and high risk of positive margins and early recurrence.
- p-value p=0.026
- p-value p=0.027
- 95% CI 20.4-33.6
- 연구 설계 cohort study
APA
Huang X, Yang H, Cai W (2026). Surgical and survival outcomes of neoadjuvant IMRT-based chemoradiotherapy versus upfront surgery in borderline resectable pancreatic cancer: a retrospective cohort study.. Frontiers in oncology, 16, 1744117. https://doi.org/10.3389/fonc.2026.1744117
MLA
Huang X, et al.. "Surgical and survival outcomes of neoadjuvant IMRT-based chemoradiotherapy versus upfront surgery in borderline resectable pancreatic cancer: a retrospective cohort study.." Frontiers in oncology, vol. 16, 2026, pp. 1744117.
PMID
41710657 ↗
Abstract 한글 요약
[BACKGROUND] Borderline resectable pancreatic cancer (BRPC) poses significant surgical challenges due to tumor-vessel involvement and high risk of positive margins and early recurrence. While neoadjuvant chemoradiotherapy has demonstrated potential benefits in this setting, the role of intensity-modulated radiation therapy (IMRT) combined with gemcitabine and nab-paclitaxel has not been specifically evaluated.
[METHODS] In this single-center retrospective cohort study, we analyzed patients with histologically confirmed borderline resectable pancreatic ductal adenocarcinoma treated between 2019 and 2022 who ultimately underwent curative-intent resection. Patients either underwent upfront surgery or received neoadjuvant chemoradiotherapy consisting of gemcitabine (1000 mg/m²) and nab-paclitaxel (125 mg/m²) combined with IMRT (36 Gy in 20 fractions), followed by surgery when feasible. Overall survival (OS) and recurrence-free survival (RFS) were calculated from the date of surgery. To address baseline imbalances, propensity score overlap weighting was performed to estimate the average treatment effect in the overlap population (ATO).
[RESULTS] A total of 152 patients were included, with 109 in the upfront surgery group and 43 in the chemoradiotherapy group. In unweighted analyses, median RFS was 27 months (95% CI 20.4-33.6) in the chemoradiotherapy group versus 13 months (95% CI 8.2-17.8) in the upfront surgery group (HR 0.61, 95% CI 0.39-0.94; p=0.026), and median OS was 33 months (95% CI 19.5-46.5) versus 21 months (95% CI 14.1-28.0) (HR 0.58, 95% CI 0.36-0.94; p=0.027). In ATO-weighted analyses, median RFS was 25 months (95% CI 14-not reached) versus 11 months (95% CI 8-17) (HR 0.56, 95% CI 0.35-0.88; p=0.013), and median OS was 33 months (95% CI 19-not reached) versus 17 months (95% CI 14-24) (HR 0.56, 95% CI 0.34-0.94; p=0.027).
[CONCLUSION] Neoadjuvant chemoradiotherapy with IMRT plus gemcitabine and nab-paclitaxel was associated with improved surgical and survival outcomes in patients with BRPC compared to upfront surgery. These findings support the integration of modern chemoradiotherapy into the neoadjuvant treatment paradigm for BRPC and warrant prospective validation.
[METHODS] In this single-center retrospective cohort study, we analyzed patients with histologically confirmed borderline resectable pancreatic ductal adenocarcinoma treated between 2019 and 2022 who ultimately underwent curative-intent resection. Patients either underwent upfront surgery or received neoadjuvant chemoradiotherapy consisting of gemcitabine (1000 mg/m²) and nab-paclitaxel (125 mg/m²) combined with IMRT (36 Gy in 20 fractions), followed by surgery when feasible. Overall survival (OS) and recurrence-free survival (RFS) were calculated from the date of surgery. To address baseline imbalances, propensity score overlap weighting was performed to estimate the average treatment effect in the overlap population (ATO).
[RESULTS] A total of 152 patients were included, with 109 in the upfront surgery group and 43 in the chemoradiotherapy group. In unweighted analyses, median RFS was 27 months (95% CI 20.4-33.6) in the chemoradiotherapy group versus 13 months (95% CI 8.2-17.8) in the upfront surgery group (HR 0.61, 95% CI 0.39-0.94; p=0.026), and median OS was 33 months (95% CI 19.5-46.5) versus 21 months (95% CI 14.1-28.0) (HR 0.58, 95% CI 0.36-0.94; p=0.027). In ATO-weighted analyses, median RFS was 25 months (95% CI 14-not reached) versus 11 months (95% CI 8-17) (HR 0.56, 95% CI 0.35-0.88; p=0.013), and median OS was 33 months (95% CI 19-not reached) versus 17 months (95% CI 14-24) (HR 0.56, 95% CI 0.34-0.94; p=0.027).
[CONCLUSION] Neoadjuvant chemoradiotherapy with IMRT plus gemcitabine and nab-paclitaxel was associated with improved surgical and survival outcomes in patients with BRPC compared to upfront surgery. These findings support the integration of modern chemoradiotherapy into the neoadjuvant treatment paradigm for BRPC and warrant prospective validation.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Self-amplifying nanomedicine reprograms redox metabolism to trigger immunogenic ferroptosis in colon cancer: multiomics identifies AMPD3 as a novel regulator.
- Selective Laser Ablation of Malignant Solid Tumors Tuned to the Resonant Wavelength of Collagen.
- Multifunctional assays and molecular simulations reveal the protective mechanisms of QNZ in mitigating PFOA-induced cytotoxicity in Nthy-ori3-1 cells.
- Revealing Inhibition of Gastric Cancer Occurrence and Metastasis by GPX3 Through Single-Cell Transcriptomics and Organoid Multimodal Technologies.
- Targeted metabolism creates possibilities for lung cancer treatment in the precision tumor era.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Impact of Skeletal Muscle-related Parameters on Survival in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine plus Nab-paclitaxel as First-line Chemotherapy.
- RNA-Micelles as Self-Assembling Structures for Efficient Co-Delivery of Synergistic siRNA and Nucleoside Analogues to Treat CRC Lung Metastasis.
- Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma.
- NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancer.
- Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection.
- SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217).